TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

OTSUKA

NeurologyDermatologyCardiovascular
Big Pharma

OTSUKA is a major pharmaceutical company focused on Neurology, Dermatology, Cardiovascular. Key products include ABILIFY MAINTENA KIT.

1997
Since
13
Drugs
-
Trials
17
Approved (2yr)

Key Drugs

REXULTI
brexpiprazole
CNS
3 indications · 2015
ABILIFY MAINTENA KIT
aripiprazole
CNS
5-HT1A receptor 3 indications · 2013
ABILIFY ASIMTUFII
aripiprazole
CNS
5-HT1A receptor 2 indications · 2023
JYNARQUE
tolvaptan
Vasopressin V2 receptor 1 indications · 2018

Recent Activity

ABILIFY MAINTENA KIT 2026-01-28
Labeling
VOYXACT 2025-11-25
Type 1 - New Molecular Entity
REXULTI 2025-05-09
Efficacy
JYNARQUE 2025-04-23
REMS
ABILIFY ASIMTUFII 2025-03-28
Efficacy
ABILIFY MAINTENA KIT 2025-03-28
Efficacy
ABILIFY MAINTENA KIT 2025-03-12
Manufacturing (CMC)
ABILIFY MYCITE KIT 2025-01-22
Labeling
ABILIFY MYCITE KIT 2025-01-22
Labeling
ABILIFY ASIMTUFII 2025-01-22
Labeling
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Neurology 37%
1 drugs Phase 3: 11 Phase 2: 4 Phase 1: 1
Dermatology 24%
0 drugs Phase 3: 8 Phase 2: 2 Phase 1: 2
Cardiovascular 23%
1 drugs Phase 3: 6 Phase 2: 3 Phase 1: 1
Oncology 11%
1 drugs Phase 3: 1 Phase 2: 1 Phase 1: 5
Respiratory 4%
0 drugs Phase 3: 1 Phase 2: 1 Phase 1: 1

Pipeline Strength Pro

Loading...

Competitors Pro

Novartis big-pharma
Oncology, Cardiovascular, Respiratory
GE HEALTHCARE specialty
Neurology, Cardiovascular, Oncology, Respiratory
Baxter specialty
Cardiovascular, Oncology, Dermatology
LEDERLE big-pharma
Cardiovascular, Neurology, Dermatology, Respiratory
GSK big-pharma
Respiratory, Oncology, Neurology